Graves' ophthalmopathy

In mild disease, patients present with eyelid retraction. Upper eyelid retraction is the most common ocular sign of Graves' orbitopathy. This finding is associated with lid lag on infraduction (Von Graefe's sign), eye globe lag on supraduction (Kocher's sign), a widened palpebral fissure during fixation (Dalrymple's sign) and inability to close the eyelids completely (lagophthalmos, Stellwag's sign). Owing to the proptosis, eyelid retraction and lagophthalmos, the cornea is more prone to dryness and may present with chemosis, punctate epithelial erosions and superior limbic keratoconjunctivitis. The patients also have a dysfunction of the lacrimal gland with a decrease in the quantity and composition of tears produced. Non-specific symptoms with these pathologies include irritation, grittiness, photophobia, tearing and blurred vision. Pain is not typical, but patients often complain of pressure in the orbit. Periorbital swelling due to inflammation can also be observed.{{citation needed|date=August 2020}}

;Eye signs{{Cite web |url=http://www.eophtha.com/eophtha/ppt/Thyroid%20Eye%20diseases.html |title=Thyroid Eye diseases | vauthors = Rao R | date = 2013 | work = Online Resources of Ophthalmology |access-date=2013-09-04 |archive-date=2014-04-17 |archive-url=https://web.archive.org/web/20140417044008/http://www.eophtha.com/eophtha/ppt/Thyroid%20Eye%20diseases.html |url-status=dead }}

In moderate active disease, the signs and symptoms are persistent and increasing and include myopathy. The inflammation and edema of the extraocular muscles lead to gaze abnormalities. The inferior rectus muscle is the most commonly affected muscle and patient may experience vertical diplopia on upgaze and limitation of elevation of the eyes due to fibrosis of the muscle. This may also increase the intraocular pressure of the eyes. The double vision is initially intermittent but can gradually become chronic. The medial rectus is the second-most-commonly-affected muscle, but multiple muscles may be affected, in an asymmetric fashion.{{citation needed|date=August 2020}}

In more severe and active disease, mass effects and cicatricial changes occur within the orbit. This is manifested by a progressive exophthalmos, a restrictive myopathy that restricts eye movements and an optic neuropathy. With enlargement of the extraocular muscle at the orbital apex, the optic nerve is at risk of compression. The orbital fat or the stretching of the nerve due to increased orbital volume may also lead to optic nerve damage. The patient experiences a loss of visual acuity, visual field defect, afferent pupillary defect, and loss of color vision. This is an emergency and requires immediate surgery to prevent permanent blindness.{{citation needed|date=August 2020}}

File:Graves Ophthalmopathy MRT 01.jpg (arrows), consistent with the diagnosis of Graves' ophthalmopathy.]]

Graves' is an orbital autoimmune disease. The thyroid-stimulating hormone receptor (TSH-R) is an antigen found in orbital fat and connective tissue, and is a target for autoimmune assault.{{citation needed|date=May 2022}}

On histological examination, there is an infiltration of the orbital connective tissue by lymphocytes, plasmocytes, and mastocytes. The inflammation results in a deposition of collagen and glycosaminoglycans in the muscles, which leads to subsequent enlargement and fibrosis. There is also an induction of the lipogenesis by fibroblasts and preadipocytes, which causes enlargement of the orbital fat and extra-ocular muscle compartments. This increase in volume of the intraorbital contents within the confines of the bony orbit may lead to dysthyroid optic neuropathy (DON), increased intraocular pressures, proptosis, and venous congestion leading to chemosis and periorbital oedema.{{cite journal | vauthors = Feldon SE, Muramatsu S, Weiner JM | title = Clinical classification of Graves' ophthalmopathy. Identification of risk factors for optic neuropathy | journal = Archives of Ophthalmology | volume = 102 | issue = 10 | pages = 1469–1472 | date = October 1984 | pmid = 6548373 | doi = 10.1001/archopht.1984.01040031189015 }}{{cite journal | vauthors = Ohtsuka K | title = Intraocular pressure and proptosis in 95 patients with Graves ophthalmopathy | journal = American Journal of Ophthalmology | volume = 124 | issue = 4 | pages = 570–572 | date = October 1997 | pmid = 9323958 | doi = 10.1016/s0002-9394(14)70883-9 }} In addition, the expansion of the intraorbital soft tissue volume may also remodel the bony orbit and enlarge it, which may be a form of auto-decompression.{{cite journal | vauthors = Tan NY, Leong YY, Lang SS, Htoon ZM, Young SM, Sundar G | title = Radiologic Parameters of Orbital Bone Remodeling in Thyroid Eye Disease | journal = Investigative Ophthalmology & Visual Science | volume = 58 | issue = 5 | pages = 2527–2533 | date = May 2017 | pmid = 28492870 | doi = 10.1167/iovs.16-21035 | doi-access = free }}

Graves' ophthalmopathy is diagnosed clinically by the presenting ocular signs and symptoms, but positive tests for antibodies (anti-thyroglobulin, anti-microsomal and anti-thyrotropin receptor) and abnormalities in thyroid hormones level (T3, T4, and TSH) help in supporting the diagnosis.{{citation needed|date=August 2020}}

Orbital imaging is an integral tool for the diagnosis of Graves' ophthalmopathy and is useful in monitoring patients for progression of the disease. It is, however, not warranted when the diagnosis can be established clinically. Ultrasonography may detect early Graves' orbitopathy in patients without clinical orbital findings. It is less reliable than the CT scan and magnetic resonance imaging (MRI), however, to assess the extraocular muscle involvement at the orbital apex, which may lead to blindness. Thus, CT scan or MRI is necessary when optic nerve involvement is suspected. On neuroimaging, the most characteristic findings are thick extraocular muscles with tendon sparing, usually bilateral, and proptosis.{{citation needed|date=August 2020}}

Mnemonic: "NO SPECS":{{cite journal | vauthors = Cawood T, Moriarty P, O'Shea D | title = Recent developments in thyroid eye disease | journal = BMJ | volume = 329 | issue = 7462 | pages = 385–390 | date = August 2004 | pmid = 15310608 | pmc = 509348 | doi = 10.1136/bmj.329.7462.385 }}

Not smoking is a common suggestion in the literature. Apart from smoking cessation, there is little definitive research in this area. In addition to the selenium studies above, some recent research also suggests that statin use may assist.{{cite web | vauthors = Kuehn BM | date = 15 December 2014 |title= Surgery, Statins Linked to Lower Graves' Complication Risk |url= http://www.medscape.com/viewarticle/836583 |publisher=Medscape Medical News }}

Even though some people undergo spontaneous remission of symptoms within a year, many need treatment. The first step is the regulation of thyroid hormone levels. Topical lubrication of the eye is used to avoid corneal damage caused by exposure. Corticosteroids are efficient in reducing orbital inflammation, but the benefits cease after discontinuation. Corticosteroids treatment is also limited because of their many side effects. Radiotherapy is an alternative option to reduce acute orbital inflammation. However, there is still controversy surrounding its efficacy. A simple way of reducing inflammation is to stop smoking, as pro-inflammatory substances are found in cigarettes. The medication teprotumumab may also be used.{{cite journal | vauthors = Shah K, Charitou M | title = A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease | language = English | journal = AACE Clinical Case Reports | volume = 8 | issue = 4 | pages = 148–149 | date = 2022-07-01 | pmid = 35959086 | pmc = 9363510 | doi = 10.1016/j.aace.2022.01.004 }}{{cite web |title=FDA approves first treatment for thyroid eye disease |url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease |archive-url=https://web.archive.org/web/20200828223737/https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease |url-status=dead |archive-date=August 28, 2020 |website=FDA |access-date=27 January 2020 |language=en |date=21 January 2020}} There is tentative evidence for selenium in mild disease.{{cite journal | vauthors = Ruchała M, Sawicka-Gutaj N | title = Advances in the pharmacological treatment of Graves' orbitopathy | journal = Expert Review of Clinical Pharmacology | volume = 9 | issue = 7 | pages = 981–989 | date = July 2016 | pmid = 26966785 | doi = 10.1586/17512433.2016.1165606 | s2cid = 9780703 }} Tocilizumab, a drug used to suppress the immune system, has also been studied as a treatment for TED. However, a Cochrane Review published in 2018 found no evidence (no relevant clinical studies were published) to show that tocilizumab works in people with TED.{{cite journal | vauthors = Hamed Azzam S, Kang S, Salvi M, Ezra DG | title = Tocilizumab for thyroid eye disease | journal = The Cochrane Database of Systematic Reviews | volume = 2018 | issue = 11 | pages = CD012984 | date = November 2018 | pmid = 30480323 | pmc = 6517231 | doi = 10.1002/14651858.CD012984.pub2 | collaboration = Cochrane Eyes and Vision Group }}

In January 2020, the US Food and Drug Administration approved teprotumumab for the treatment of Graves' ophthalmopathy.

There is some evidence that a total or sub-total thyroidectomy may assist in reducing levels of TSH receptor antibodies (TRAbs) and as a consequence reduce the eye symptoms, perhaps after a 12-month lag.{{cite journal | vauthors = Takamura Y, Nakano K, Uruno T, Ito Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A | display-authors = 6 | title = Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy | journal = Endocrine Journal | volume = 50 | issue = 5 | pages = 595–601 | date = October 2003 | pmid = 14614216 | doi = 10.1507/endocrj.50.595 | doi-access = free }}{{cite journal | vauthors = De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, Iacovo AD, Paglionico VA, Sinisi AA, Wall JR, Bizzarro A, Bellastella A | display-authors = 6 | title = Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study | journal = Endocrine | volume = 41 | issue = 2 | pages = 320–326 | date = April 2012 | pmid = 22169963 | doi = 10.1007/s12020-011-9559-x | s2cid = 8197441 }}{{cite journal | vauthors = Bhargav PR, Sabaretnam M, Kumar SC, Zwalitha S, Devi NV | title = Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series | journal = The Indian Journal of Surgery | volume = 79 | issue = 6 | pages = 521–526 | date = December 2017 | pmid = 29217903 | pmc = 5711711 | doi = 10.1007/s12262-016-1516-8 }}{{cite journal | vauthors = Nart A, Uslu A, Aykas A, Yuzbasioglu F, Dogan M, Demirtas O, Simsek C | title = Total thyroidectomy for the treatment of recurrent graves' disease with ophthalmopathy | journal = Asian Journal of Surgery | volume = 31 | issue = 3 | pages = 115–118 | date = July 2008 | pmid = 18658008 | doi = 10.1016/S1015-9584(08)60070-6 | doi-access = }}{{cite journal | vauthors = Lowery AJ, Kerin MJ | title = Graves' ophthalmopathy: the case for thyroid surgery | journal = The Surgeon | volume = 7 | issue = 5 | pages = 290–296 | date = October 2009 | pmid = 19848063 | doi = 10.1016/s1479-666x(09)80007-3 }} However, a 2015 meta review found no such benefits,{{cite journal | vauthors = Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K | title = Thyroid surgery for Graves' disease and Graves' ophthalmopathy | journal = The Cochrane Database of Systematic Reviews | issue = 11 | pages = CD010576 | date = November 2015 | pmid = 26606533 | doi = 10.1002/14651858.CD010576.pub2 | pmc = 11189635 }} and there is some evidence that suggests that surgery is no better than medication.{{cite journal | vauthors = Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O | title = TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study | journal = European Journal of Endocrinology | volume = 158 | issue = 1 | pages = 69–75 | date = January 2008 | pmid = 18166819 | doi = 10.1530/EJE-07-0450 | doi-access = }}

Surgery may be done to decompress the orbit, to improve the proptosis and to address the strabismus causing diplopia. Surgery is performed once the patient’s disease has been stable for at least six months. In severe cases, however, surgery becomes urgent to prevent blindness from optic nerve compression. Because the eye socket is bone, there is nowhere for eye muscle swelling to be accommodated, and as a result the eye is pushed forward into a protruded position. Orbital decompression involves removing some bone from the eye socket to open up one or more sinuses and so make space for the swollen tissue and allow the eye to move back into normal position and also relieve compression of the optic nerve that can threaten sight.{{citation needed|date=May 2022}}

Eyelid surgery is the most common surgery performed on Graves ophthalmopathy patients. Lid-lengthening surgeries can be done on upper and lower eyelid to correct the patient's appearance and the ocular surface exposure symptoms. Marginal myotomy of levator palpebrae muscle can reduce the palpebral fissure height by 2–3 mm. When there is a more severe upper lid retraction or exposure keratitis, marginal myotomy of levator palpebrae associated with lateral tarsal canthoplasty is recommended. This procedure can lower the upper eyelid by as much as 8 mm. Other approaches include müllerectomy (resection of the Müller muscle), eyelid spacer grafts, and recession of the lower eyelid retractors. Blepharoplasty can also be done to debulk the excess fat in the lower eyelid.{{cite web|author=Muratet JM |title=Eyelid retraction |work=Ophthalmic Plastic Surgery |url=http://www.snof.org/chirurgie/eyelidsurg6.html |publisher=Le Syndicat National des Ophtalmologistes de France |access-date=2007-07-12 |url-status=dead |archive-url=https://web.archive.org/web/20070609030423/http://www.snof.org/chirurgie/eyelidsurg6.html |archive-date=June 9, 2007 }}

A summary of treatment recommendations was published in 2015 by an Italian taskforce,{{cite journal | vauthors = Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F | title = Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement | journal = Journal of Endocrinological Investigation | volume = 38 | issue = 4 | pages = 481–487 | date = April 2015 | pmid = 25722226 | pmc = 4374116 | doi = 10.1007/s40618-015-0257-z }} which largely supports the other studies.

Risk factors of progressive and severe thyroid-associated orbitopathy are:{{citation needed|date=August 2020}}

• Age greater than 50 years
• Rapid onset of symptoms under 3 months
• Cigarette smoking
• Diabetes
• Severe or uncontrolled hyperthyroidism
• Presence of pretibial myxedema
• High cholesterol levels (hyperlipidemia)
• Peripheral vascular disease

The pathology mostly affects persons of 30 to 50 years of age. Females are four times more likely to develop Graves' than males. When males are affected, they tend to have a later onset and a poor prognosis. A study demonstrated that at the time of diagnosis, 90% of the patients with clinical orbitopathy were hyperthyroid according to thyroid function tests, while 3% had Hashimoto's thyroiditis, 1% were hypothyroid and 6% did not have any thyroid function tests abnormality.{{cite journal | vauthors = Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA | title = Clinical features of Graves' ophthalmopathy in an incidence cohort | journal = American Journal of Ophthalmology | volume = 121 | issue = 3 | pages = 284–290 | date = March 1996 | pmid = 8597271 | doi = 10.1016/s0002-9394(14)70276-4 }} Of patients with Graves' hyperthyroidism, 20 to 25 percent have clinically obvious Graves' ophthalmopathy, while only 3–5% will develop severe ophthalmopathy.{{cite web |title=Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy) | vauthors = Davies TF, Burch HB | veditors = Ross DS, Martin KA |publisher=UpToDate |date=September 2009 |url=http://www.uptodate.com/contents/pathogenesis-and-clinical-features-of-graves-ophthalmopathy-orbitopathy }}{{cite journal | vauthors = Bartalena L, Marcocci C, Pinchera A | title = Graves' ophthalmopathy: a preventable disease? | journal = European Journal of Endocrinology | volume = 146 | issue = 4 | pages = 457–461 | date = April 2002 | pmid = 11916611 | doi = 10.1530/eje.0.1460457 | doi-access = free }}

In medical literature, Anglo-Irish surgeon Robert James Graves, in 1835, was the first to describe the association of a thyroid goitre with exophthalmos (proptosis) of the eye.{{WhoNamedIt|doctor|695|Robert James Graves}} Graves' ophthalmopathy may occur before, with, or after the onset of overt thyroid disease and usually has a slow onset over many months.{{citation needed|date=May 2022}}

• Infiltrative ophthalmopathy
• Exophthalmos

{{Reflist}}

{{refbegin}}

• {{cite journal | vauthors = Behbehani R, Sergott RC, Savino PJ | title = Orbital radiotherapy for thyroid-related orbitopathy | journal = Current Opinion in Ophthalmology | volume = 15 | issue = 6 | pages = 479–482 | date = December 2004 | pmid = 15523191 | doi = 10.1097/01.icu.0000144388.89867.03 | s2cid = 31340321 }}
• {{cite journal | vauthors = Boncoeur MP | title = [Dysthyroid orbitopathy: imaging] | language = fr | journal = Journal Français d'Ophtalmologie | volume = 27 | issue = 7 | pages = 815–818 | date = September 2004 | pmid = 15499283 | doi = 10.1016/S0181-5512(04)96221-3 | trans-title = Imaging techniques in Graves disease : Dysthyroid orbitopathy | id = {{INIST|16100159}} }}
• {{cite journal | vauthors = Boulos PR, Hardy I | title = Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review | journal = Current Opinion in Ophthalmology | volume = 15 | issue = 5 | pages = 389–400 | date = October 2004 | pmid = 15625899 | doi = 10.1097/01.icu.0000139992.15463.1b | s2cid = 23194226 }}
• {{cite journal | vauthors = Camezind P, Robert PY, Adenis JP | title = [Clinical signs of dysthyroid orbitopathy] | language = fr | journal = Journal Français d'Ophtalmologie | volume = 27 | issue = 7 | pages = 810–814 | date = September 2004 | pmid = 15499282 | doi = 10.1016/S0181-5512(04)96220-1 | trans-title = Clinical signs of dysthyroid orbitopathy : Dysthyroid orbitopathy | id = {{INIST|16100158}} }}
• {{cite book | vauthors = Duker JS, Yanoff M |title=Ophthalmology |edition=2nd |chapter=chapt 95 |publisher=C.V. Mosby |location=Saint Louis |year=2004 |isbn=978-0-323-02907-0 }}
• {{cite journal | vauthors = Morax S, Ben Ayed H | title = [Orbital decompression for dysthyroid orbitopathy: a review of techniques and indications] | language = fr | journal = Journal Français d'Ophtalmologie | volume = 27 | issue = 7 | pages = 828–844 | date = September 2004 | pmid = 15499287 | doi = 10.1016/s0181-5512(04)96225-0 | trans-title = Orbital decompression for dysthyroid orbitopathy: a review of techniques and indications }}
• {{cite journal | vauthors = Rose JG, Burkat CN, Boxrud CA | title = Diagnosis and management of thyroid orbitopathy | journal = Otolaryngologic Clinics of North America | volume = 38 | issue = 5 | pages = 1043–1074 | date = October 2005 | pmid = 16214573 | doi = 10.1016/j.otc.2005.03.015 }}

{{refend}}

{{Medical resources

| DiseasesDB = 5419

| ICD10 = {{ICD10|H|06|2|h|00}}*

| ICD9 = {{ICD9|242.90}}

| ICDO =

| OMIM =

| MedlinePlus =

| eMedicineSubj = oph

| eMedicineTopic = 237

| eMedicine_mult = {{eMedicine2|ent|169}} {{eMedicine2|neuro|476}} {{eMedicine2|radio|485}}

| MeshID = D049970

}}

{{Thyroid disease}}

{{Eye pathology}}

{{Authority control}}

Category:Thyroid disease

Category:Eye diseases

Category:Autoimmune diseases

Category:Thyroid